Dr. Stavros Melemenidis | Nanotheranostics Awards | Best Researcher Award

Posted on by ScienceFather

Dr. Stavros Melemenidis | Nanotheranostics Awards | Best Researcher Award

Dr. Stavros Melemenidis , Stanford University School of Medicine , United States

Stavros Melemenidis, DPhil, is a distinguished figure in the field of Radiation Oncology, currently serving as Director of Pre-clinical Radiotherapy and Research Scientist at Stanford University’s Department of Radiation Oncology in Stanford, CA, USA. He completed his DPhil in Radiation Biology at the University of Oxford, where his research focused on molecular targeted imaging methods for lung metastasis and angiogenesis detection. Dr. Melemenidis holds a diverse educational background including degrees from UCLA and the University of Liverpool. His expertise spans preclinical radiotherapy, ultra-high dose-rate irradiation experiments, and the development of advanced imaging probes and animal models for cancer research. Dr. Melemenidis is recognized for his contributions to radiation therapy and imaging sciences, employing innovative techniques to advance cancer treatment and research.

Professional Profile:

Scopus

🎓Education:

Stavros Melemenidis, DPhil, has pursued an extensive educational journey encompassing a diverse array of disciplines. He earned his DPhil in Radiation Biology from the University of Oxford, UK, focusing on the development of molecular targeted imaging methods for the detection of lung metastasis and angiogenesis. His academic credentials also include a Cert. in Medical Physics from UCLA, USA, an M.Sc. in Radiation Biology from the University of Oxford, UK, and an M.Sc. in Radiometrics; Instrumentation and Modelling from the University of Liverpool, UK. Dr. Melemenidis began his academic path with a B.Sc. in Physics: Medical Applications from the University of Liverpool and an A.Eng. in PC Systems and Peripheral Equipment from IIEK Neapoleos, Technical College, Greece. This diverse educational background has equipped him with expertise spanning radiation biology, medical physics, instrumentation, and modelling, contributing significantly to his research and leadership roles in the field of Radiation Oncology at Stanford University.

🏢Work Experience:

Stavros Melemenidis, DPhil, holds key positions in the field of Radiation Oncology at Stanford University in Stanford, CA, USA. Since January 2023, he has served as the Director of Pre-clinical Radiotherapy within the Department of Radiation Oncology, overseeing advanced research initiatives. Prior to this role, Dr. Melemenidis has been integral to the Division of Radiation Therapy as a Research Scientist since February 2020, contributing to innovative studies in radiation oncology. His earlier career includes impactful roles as a Postdoctoral Fellow at Stanford University from February 2016 to June 2020, where he focused on developing in vivo mouse tumor models and integrating imaging techniques with radiotherapy and immunotherapy. Previously, he was a Postdoctoral Fellow at the University of Oxford’s Department of Radiation Oncology from January 2015 to September 2015, conducting research on novel imaging probes for metastasis and angiogenesis detection. These experiences underscore Dr. Melemenidis’s dedication to advancing preclinical and clinical applications in radiation oncology through pioneering research and leadership.

Publication Top Notes:

  • Human enteroids as a tool to study conventional and ultra-high dose rate radiation
    • Authors: Klett, K.C., Martin-Villa, B.C., Villarreal, V.S., Loo Jr, B.W., Heilshorn, S.C.
    • Citations: 1
  • Real-time optical oximetry during FLASH radiotherapy using a phosphorescent nanoprobe
    • Authors: Ha, B., Liang, K., Liu, C., Loo, B.W., Pratx, G.
    • Citations: 4
  • Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension
    • Authors: Taylor, S., Isobe, S., Cao, A., Snyder, M.P., Rabinovitch, M.
    • Citations: 10
  • Design and validation of a dosimetric comparison scheme tailored for ultra-high dose-rate electron beams to support multicenter FLASH preclinical studies
    • Authors: Jorge, P.G., Melemenidis, S., Grilj, V., Loo, B.W., Bailat, C.
    • Citations: 9

 

 

Prof Vladislav Kostov-Kytin | Nanotheranostics Awards | Best Researcher Award

Posted on by ScienceFather

Prof Vladislav Kostov-Kytin | Nanotheranostics Awards | Best Researcher Award

Prof Vladislav Kostov-Kytin , Institute of Mineralogy and Crystallography, Sofia, Bulgaria 

Vladislav Kostov-Kytin is a Full Professor at the Institute of Mineralogy and Crystallography, Bulgarian Academy of Sciences, a position he has held since 2020. With over 30 years of experience, he specializes in the synthesis of advanced materials such as lead-antimony chlorine sulphosalts, titanosilicates, zirconosilicates, stannosilicates, and alkaline silicates. His research focuses on employing powder X-ray diffraction and Rietveld refinement software for detailed structural analysis. Prof. Kostov is renowned for his extensive contributions to inorganic synthesis and X-ray phase analysis, evident in his more than 70 publications in reputable journals like Scopus and Web of Science. His work also includes exploring the mineralogical diversity of Bulgaria, aiding in the selection and characterization of raw materials crucial for material science advancements.

Professional Profile:

Orcid

Education:

Prof. Vladislav Kostov-Kytin has attained a doctoral degree (Ph.D.), specializing in fields typically related to mineralogy, crystallography, or materials science. Specific details regarding the institution and year of graduation would typically be outlined in his curriculum vitae or academic profile. These documents provide a comprehensive overview of his educational background, including the focus of his doctoral research and any related academic achievements. For precise information, reviewing his official academic profile or publications would be advisable.

Work Experience:

Prof. Vladislav Kostov-Kytin has held the position of Full Professor at the Institute of Mineralogy and Crystallography, Bulgarian Academy of Sciences. Prior to assuming this role, details of his earlier positions, including research roles, teaching appointments, or other academic positions, would typically be included in his professional biography or curriculum vitae. For precise information regarding his career trajectory, consulting his official academic profile, university website, or academic publications is recommended, as these sources often provide comprehensive insights into his educational background and professional journey.

Publication Top Notes:

  • Further on the Choice of Space Group for Scapolite Group Members and Genetic Considerations about the Si-Al Ordering in Their Framework Construction
    • Journal: Minerals
    • Publication Date: 2024-05-28
    • DOI: 10.3390/min14060556
    • Contributors: Vladislav Kostov-Kytin; Milen Kadiyski; Rositsa Nikolova
  • New Data on Crystal Phases in the System MgSO4–OC(NH2)2–H2O
    • Journal: Crystals
    • Publication Date: 2024-02-27
    • DOI: 10.3390/cryst14030227
    • Contributors: Rositsa Nikolova; Vladislav Kostov-Kytin; Nadia Petrova; Krasimir Kossev; Rositsa Titorenkova; Gergana Velyanova
  • Crystal chemical investigations of epidote group minerals from two Bulgarian localities: Effects of Mn content and Mn/Fe ratio on the structural peculiarities
    • Journal: Geologica Balcanica
    • Publication Date: 2023-10-20
    • DOI: 10.52321/GeolBalc.52.3.95
    • Contributors: Vladislav Kostov-Kytin; Rositsa Nikolova; Sylvina Georgieva; Ivayla Sopotenska; Milen Kadiyski; Rossitsa Vassileva
  • U-Pb dating and composition of columbite from Vishteritsa: Implication for timing of granite magmatism and rare-element granitic pegmatites in the Western Rhodopes, Bulgaria
    • Journal: Geologica Carpathica
    • Publication Date: 2021-07-28
    • DOI: 10.31577/GeolCarp.72.3.2
    • Contributors: Irena Peytcheva; Albrecht Von Quadt; Vladislav Kostov-Kytin; Milen Kadiyski; Milen Stavrev
  • TG/DTG-DSC and high temperature in-situ XRD analysis of natural thaumasite
    • Journal: Thermochimica Acta
    • Publication Date: 2021-03
    • DOI: 10.1016/j.tca.2021.178863

 

 

Dr. Seong Jae Kang | Nanotheranostics Award | Best Researcher Award

Posted on by ScienceFather

Dr. Seong Jae Kang | Nanotheranostics Award | Best Researcher Award

Dr. Seong Jae Kang  , GC Biopharma , South Korea

Seong Jae Kang, Ph.D., is a dedicated researcher specializing in translational science and biomedical research. Currently based at GC biopharma in the Republic of Korea since December 2021, he contributes to the Department of Research & Early Development’s Translational Science Team. Prior to this role, he held postdoctoral fellowships at prestigious institutions including Northwestern University Feinberg School of Medicine in Chicago, IL, USA, and the Korea Institute of Science and Technology (KIST) in South Korea. Dr. Kang earned his Ph.D. in Biomedical Laboratory Science from Yonsei University, where he achieved an outstanding academic record under the mentorship of Yong Serk Park. His research interests encompass tumor targeted therapy, immunotherapy, lipid nanoparticles, chemotherapy, gene therapy, biomarker discovery, and brain tumor targeting, with a focus on glioma treatment and genome editing. Dr. Kang possesses extensive technical skills in cell culture, cytotoxicity testing, flow cytometry, confocal microscopy, and various cellular and molecular analyses. His career reflects a commitment to advancing medical science through innovative research and application in biopharmaceutical development.

Professional Profile:

Google Scholar

 🎓Education:

Seong Jae Kang, Ph.D., pursued his academic journey in Biomedical Laboratory Science at Yonsei University, Republic of Korea. He earned his Ph.D. from 2012 to 2018 with an exceptional cumulative graduate GPA of 4.13/4.3 under the guidance of his academic adviser, Yong Serk Park (parkys@yonsei.ac.kr). Prior to his doctoral studies, Seong Jae completed his B.S. in Biomedical Laboratory Science at Yonsei University from 2006 to 2012, achieving a cumulative bachelor GPA of 3.77/4.3. Additionally, he holds certification as a medical laboratory technologist, reflecting his dedication to acquiring comprehensive expertise in biomedical research and laboratory sciences.

🏢Work Experience:

Dr. Seong Jae Kang has built a distinguished career in translational science and biomedical research through several pivotal roles. Currently serving as a Researcher in the Translational Science Team at GC biopharma, Republic of Korea since December 2021, he contributes to the Department of Research & Early Development. Prior to this, Dr. Kang held significant positions including Postdoctoral Fellow at the Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA (February 2019 – October 2021), and at the Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Republic of Korea (February 2018 – January 2019). His research focuses on advancing areas such as tumor targeted therapy, immunotherapy, lipid nanoparticles, chemotherapy, gene therapy, biomarker discovery, brain tumor targeting, glioma treatment, and genome editing. Dr. Kang’s expertise encompasses a wide range of technical skills including cell culture, cytotoxicity testing, flow cytometry, confocal microscopy, and various cellular and molecular analyses, underscoring his commitment to driving innovation in medical science and biopharmaceutical development.

Publication Top Notes:

  • Myeloid-derived suppressive cells promote B cell–mediated immunosuppression via transfer of PD-L1 in glioblastoma
    • Cited By: 110
    • Year: 2019
    • Journal: Cancer Immunology Research
  • Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer
    • Cited By: 105
    • Year: 2019
    • Journal: Theranostics
  • Cancer-targeted nucleic acid delivery and quantum dot imaging using EGF receptor aptamer-conjugated lipid nanoparticles
    • Cited By: 80
    • Year: 2017
    • Journal: Scientific Reports
  • ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
    • Cited By: 55
    • Year: 2021
    • Journal: Nature Cancer
  • Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis
    • Cited By: 49
    • Year: 2018